Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Besancon
With
Clinical Investigation Centre for Innovative Technology Network
University Hospital, Grenoble
CH Le Vinatier - Service de Psychiatrie (Dr Emmanuel POULET)
Rennes University Hospital
EPS Ville-Evrard - Unité de Recherche Clinique (Dr Dominique JANUEL)
Hôpital Civil de Strasbourg - Service de Psychiatrie (Pr G.Bertschy)
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
subject whose MDD are single or recurrent without psychotic features according to DSM-IV-TR
subject with a diagnosis of resistant major depression (≥1 failed antidepressant treatments for the current depressive episode)
HDRS-21 score ≥ 21
drug treatment by SSRIs or SNRIs for unipolar patients or with Lithium for bipolar patients for at least 4 weeks
right-handed patients
without severe progressive somatic pathology (especially tumor diseases, degenerative diseases)
without severe cognitive impairment making psychometric evaluation impossible
excepted antidepressant or Lithium treatment, psychotropic following are tolerated during the course of the study : hydroxyzin; cyamemazin (up to 100 mg/day) ; hypnotics (imidazopyridin).
You may not be if
subject treated with antipsychotics or mood stabilizers or anticonvulsants or by ECT or rTMS for the current depressive episode
subject resistant to SSRIs or SNRIs for unipolar patients or with Lithium for bipolar patients
subject with mixed features
pregnancy and/or lactation
presence of a specific contraindication for tDCS (e.g., personal history of epilepsy, metallic head implant, cardiac pacemaker)
Clareo Health | tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients
